DNA Polymerase Zeta Inactivation in Prostate Cancer
Abstract
Not all prostate cancer patients respond in the same way to therapies. For example, some cancers respond well to hormone therapies, and others to radiation therapy. A major reason for these differences is that different genetic changes underlie individual cancers. In order to personalize therapy and make it much more effective, it is important to take advantage of genetic analyses and determine, as early as possible during treatment, the therapeutic strategies that will be most effective to cure or control the cancer. Although it is the most common cancer in American men, more than a quarter of primary prostate cancers of both good and poor clinical prognosis are driven by unknown molecular changes in the genome.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2018
- Accession Number
- AD1060428
Entities
People
- Richard D. Wood
Organizations
- University of Texas at Austin